{"pmid":32412329,"title":"An Ounce of Prevention May Prevent Hospitalization.","text":["An Ounce of Prevention May Prevent Hospitalization.","Physiol Rev","Barker, Andrew B","Wagener, Brant M","32412329"],"journal":"Physiol Rev","authors":["Barker, Andrew B","Wagener, Brant M"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32412329","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1152/physrev.00017.2020","keywords":["sars-cov-2","acute respiratory distress syndrome","coagulopathy","tissue plasminogen activator","tranexamic acid"],"topics":["Prevention"],"weight":1,"_version_":1666897319262420993,"score":9.490897,"similar":[{"pmid":32211279,"pmcid":"PMC7089620","title":"An Ounce of Prevention: Coronavirus (COVID-19) and Mass Gatherings.","text":["An Ounce of Prevention: Coronavirus (COVID-19) and Mass Gatherings.","Widespread, non-stop, and often sensational coverage of the coronavirus (COVID-19) has caught many governments flat-footed in efforts to protect the health and safety of their citizens. In response to the current global health event, the World Health Organization (WHO) declared COVID-19 a pandemic. Mass gatherings present a historic challenge in protecting the health and safety of attendees. The majority of the prominent mass gatherings are religious in nature. Global sporting events, such as the Olympics and the World Cup, pose unique health risks to attendees and host nations. Deferment or cancellation of such mass gatherings may exert an extraordinary economic loss to the host nation. Universal adoption of best practices for infection control is the surest way for governments to prepare for mass gatherings. In these uncertain times, it is up to intergovernmental organizations to be the voice of reason.","Cureus","Escher, Allan R Jr","32211279"],"abstract":["Widespread, non-stop, and often sensational coverage of the coronavirus (COVID-19) has caught many governments flat-footed in efforts to protect the health and safety of their citizens. In response to the current global health event, the World Health Organization (WHO) declared COVID-19 a pandemic. Mass gatherings present a historic challenge in protecting the health and safety of attendees. The majority of the prominent mass gatherings are religious in nature. Global sporting events, such as the Olympics and the World Cup, pose unique health risks to attendees and host nations. Deferment or cancellation of such mass gatherings may exert an extraordinary economic loss to the host nation. Universal adoption of best practices for infection control is the surest way for governments to prepare for mass gatherings. In these uncertain times, it is up to intergovernmental organizations to be the voice of reason."],"journal":"Cureus","authors":["Escher, Allan R Jr"],"date":"2020-03-27T11:00:00Z","year":2020,"_id":"32211279","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.7759/cureus.7345","keywords":["2019-ncov","coronavirus","covid-19","ebola","iso 31000","mass gathering","olympics","religious pilgrimage","thermal scanners","world health organization"],"topics":["Prevention"],"weight":1,"_version_":1666138492378284035,"score":76.819},{"pmid":32329246,"title":"Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.","text":["Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.","The global pandemic of coronavirus disease 2019 (COVID-19) is associated with the development of acute respiratory distress syndrome (ARDS), which requires ventilation in critically ill patients. The pathophysiology of ARDS results from acute inflammation within the alveolar space and prevention of normal gas exchange. The increase in proinflammatory cytokines within the lung leads to recruitment of leukocytes, further propagating the local inflammatory response. A consistent finding in ARDS is the deposition of fibrin in the air spaces and lung parenchyma. COVID-19 patients show elevated D-Dimers and fibrinogen. Fibrin deposits are found in the lungs of patients due to the dysregulation of the coagulation and fibrinolytic systems. Tissue factor (TF) is exposed on damaged alveolar endothelial cells and on the surface of leukocytes promoting fibrin deposition, while significantly elevated levels of plasminogen activator inhibitor 1 (PAI-1) from lung epithelium and endothelial cells create a hypofibrinolytic state. Prophylaxis treatment of COVID-19 patients with low molecular weight heparin (LMWH) is important to limit coagulopathy. However, to degrade pre-existing fibrin in the lung it is essential to promote local fibrinolysis. In this review, we discuss the repurposing of fibrinolytic drugs, namely tissue-type plasminogen activator (tPA), to treat COVID-19 associated ARDS. tPA is an approved intravenous thrombolytic treatment, and the nebulizer form has been shown to be effective in plastic bronchitis and is currently in Phase II clinical trial. Nebulizer plasminogen activators may provide a targeted approach in COVID-19 patients to degrade fibrin and improving oxygenation in critically ill patients.","J Thromb Haemost","Whyte, Claire S","Morrow, Gael B","Mitchell, Joanne L","Chowdary, Pratima","Mutch, Nicola J","32329246"],"abstract":["The global pandemic of coronavirus disease 2019 (COVID-19) is associated with the development of acute respiratory distress syndrome (ARDS), which requires ventilation in critically ill patients. The pathophysiology of ARDS results from acute inflammation within the alveolar space and prevention of normal gas exchange. The increase in proinflammatory cytokines within the lung leads to recruitment of leukocytes, further propagating the local inflammatory response. A consistent finding in ARDS is the deposition of fibrin in the air spaces and lung parenchyma. COVID-19 patients show elevated D-Dimers and fibrinogen. Fibrin deposits are found in the lungs of patients due to the dysregulation of the coagulation and fibrinolytic systems. Tissue factor (TF) is exposed on damaged alveolar endothelial cells and on the surface of leukocytes promoting fibrin deposition, while significantly elevated levels of plasminogen activator inhibitor 1 (PAI-1) from lung epithelium and endothelial cells create a hypofibrinolytic state. Prophylaxis treatment of COVID-19 patients with low molecular weight heparin (LMWH) is important to limit coagulopathy. However, to degrade pre-existing fibrin in the lung it is essential to promote local fibrinolysis. In this review, we discuss the repurposing of fibrinolytic drugs, namely tissue-type plasminogen activator (tPA), to treat COVID-19 associated ARDS. tPA is an approved intravenous thrombolytic treatment, and the nebulizer form has been shown to be effective in plastic bronchitis and is currently in Phase II clinical trial. Nebulizer plasminogen activators may provide a targeted approach in COVID-19 patients to degrade fibrin and improving oxygenation in critically ill patients."],"journal":"J Thromb Haemost","authors":["Whyte, Claire S","Morrow, Gael B","Mitchell, Joanne L","Chowdary, Pratima","Mutch, Nicola J"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329246","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/jth.14872","keywords":["fibrin","fibrinolysis","plasminogen activator inhibitor 1","respiratory distress syndrome (adult)","sars virus","tissue plasminogen activator"],"locations":["ARDS","nebulizer","Nebulizer"],"e_drugs":["Heparin, Low-Molecular-Weight"],"topics":["Treatment"],"weight":1,"_version_":1666138494690394113,"score":63.356476},{"pmid":32378030,"pmcid":"PMC7202903","title":"COVID-19-Related Stroke.","text":["COVID-19-Related Stroke.","The COVID-19 pandemic is associated with neurological symptoms and complications including stroke. There is hypercoagulability associated with COVID-19 that is likely a \"sepsis-induced coagulopathy\" and may predispose to stroke. The SARS-CoV-2 virus binds to angiotensin-converting enzyme 2 (ACE2) present on brain endothelial and smooth muscle cells. ACE2 is a key part of the renin angiotensin system (RAS) and a counterbalance to angiotensin-converting enzyme 1 (ACE1) and angiotensin II. Angiotensin II is proinflammatory, is vasoconstrictive, and promotes organ damage. Depletion of ACE2 by SARS-CoV-2 may tip the balance in favor of the \"harmful\" ACE1/angiotensin II axis and promote tissue injury including stroke. There is a rationale to continue to treat with tissue plasminogen activator for COVID-19-related stroke and low molecular weight heparinoids may reduce thrombosis and mortality in sepsis-induced coagulopathy.","Transl Stroke Res","Hess, David C","Eldahshan, Wael","Rutkowski, Elizabeth","32378030"],"abstract":["The COVID-19 pandemic is associated with neurological symptoms and complications including stroke. There is hypercoagulability associated with COVID-19 that is likely a \"sepsis-induced coagulopathy\" and may predispose to stroke. The SARS-CoV-2 virus binds to angiotensin-converting enzyme 2 (ACE2) present on brain endothelial and smooth muscle cells. ACE2 is a key part of the renin angiotensin system (RAS) and a counterbalance to angiotensin-converting enzyme 1 (ACE1) and angiotensin II. Angiotensin II is proinflammatory, is vasoconstrictive, and promotes organ damage. Depletion of ACE2 by SARS-CoV-2 may tip the balance in favor of the \"harmful\" ACE1/angiotensin II axis and promote tissue injury including stroke. There is a rationale to continue to treat with tissue plasminogen activator for COVID-19-related stroke and low molecular weight heparinoids may reduce thrombosis and mortality in sepsis-induced coagulopathy."],"journal":"Transl Stroke Res","authors":["Hess, David C","Eldahshan, Wael","Rutkowski, Elizabeth"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32378030","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s12975-020-00818-9","keywords":["angiotensin-converting enzyme 2 (ace2)","covid-19","coagulopathy","sars-cov-2","sepsis","stroke"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666597097428746242,"score":48.54334},{"pmid":32399806,"title":"Is COVID-19 a New Hematologic Disease?","text":["Is COVID-19 a New Hematologic Disease?","SARS-CoV-2 viruses are positive single-stranded RNA viruses, whose infection can be asymptomatic or lead to the coronavirus disease 2019 (Covid-19). Covid-19 is a respiratory infection with a significant impact on the hematopoietic system and hemostasis leading to several cardiovascular complications. Hematologic consequences of this new infection allowed medical community to start new treatment approaches concerning infection going from targeted anti-inflammatory drugs to anticoagulation or stem cell therapies. A better understanding of Covid-19 pathophysiology, in particular hematological disorders, will help to choose appropriate treatment strategies.","Stem Cell Rev Rep","Debuc, Benjamin","Smadja, David M","32399806"],"abstract":["SARS-CoV-2 viruses are positive single-stranded RNA viruses, whose infection can be asymptomatic or lead to the coronavirus disease 2019 (Covid-19). Covid-19 is a respiratory infection with a significant impact on the hematopoietic system and hemostasis leading to several cardiovascular complications. Hematologic consequences of this new infection allowed medical community to start new treatment approaches concerning infection going from targeted anti-inflammatory drugs to anticoagulation or stem cell therapies. A better understanding of Covid-19 pathophysiology, in particular hematological disorders, will help to choose appropriate treatment strategies."],"journal":"Stem Cell Rev Rep","authors":["Debuc, Benjamin","Smadja, David M"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32399806","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s12015-020-09987-4","keywords":["coagulopathy","covid-19","cytokine","d-dimers","inflammation","lymphopenia","mesenchymal stem cells","sars-cov-2","stem cells","thrombosis"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666865855078596609,"score":48.54334},{"pmid":32434133,"title":"The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities.","text":["The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities.","This paper collates the pathological findings from initial published autopsy reports on 23 patients with coronavirus disease 2019 (COVID-19) from 5 centers in the United States of America, including 3 cases from Houston, Texas. Findings confirm that COVID-19 is a systemic disease with major involvement of the lungs and heart. Acute COVID-19 pneumonia has features of a distinctive acute interstitial pneumonia with a diffuse alveolar damage component, coupled with microvascular involvement with intra- and extravascular fibrin deposition and intravascular trapping of neutrophils, and, frequently, with formation of microthombi in arterioles. Major pulmonary thromboemboli with pulmonary infarcts and/or hemorrhage occurred in 5 of the 23 patients. Two of the Houston cases had interstitial pneumonia with diffuse alveolar damage pattern. One of the Houston cases had multiple bilateral segmental pulmonary thromboemboli with infarcts and hemorrhages coupled with, in nonhemorrhagic areas, a distinctive interstitial lymphocytic pneumonitis with intra-alveolar fibrin deposits and no hyaline membranes, possibly representing a transition form to acute fibrinous and organizing pneumonia. Multifocal acute injury of cardiac myocytes was frequently observed. Lymphocytic myocarditis was reported in 1 case. In addition to major pulmonary pathology, the 3 Houston cases had evidence of lymphocytic pericarditis, multifocal acute injury of cardiomyocytes without inflammatory cellular infiltrates, depletion of splenic white pulp, focal hepatocellular degeneration and rare glomerular capillary thrombosis. Each had evidence of chronic cardiac disease: hypertensive left ventricular hypertrophy (420 g heart), dilated cardiomyopathy (1070 g heart), and hypertrophic cardiomyopathy (670 g heart). All 3 subjects were obese (BMIs of 33.8, 51.65, and 35.2 Kg/m(2)). Overall, the autopsy findings support the concept that the pathogenesis of severe COVID-19 disease involves direct viral-induced injury of multiple organs, including heart and lungs, coupled with the consequences of a procoagulant state with coagulopathy.","Cardiovasc Pathol","Buja, Louis Maximilian","Wolf, Dwayne","Zhao, Bihong","Akkanti, Bindu","McDonald, Michelle","Lelenwa, Laura","Reilly, Noah","Ottaviani, Giulia","Elghetany, M Tarek","Trujillo, Daniel Ocazionez","Aisenberg, Gabriel M","Madjid, Mohammad","Kar, Biswajit","32434133"],"abstract":["This paper collates the pathological findings from initial published autopsy reports on 23 patients with coronavirus disease 2019 (COVID-19) from 5 centers in the United States of America, including 3 cases from Houston, Texas. Findings confirm that COVID-19 is a systemic disease with major involvement of the lungs and heart. Acute COVID-19 pneumonia has features of a distinctive acute interstitial pneumonia with a diffuse alveolar damage component, coupled with microvascular involvement with intra- and extravascular fibrin deposition and intravascular trapping of neutrophils, and, frequently, with formation of microthombi in arterioles. Major pulmonary thromboemboli with pulmonary infarcts and/or hemorrhage occurred in 5 of the 23 patients. Two of the Houston cases had interstitial pneumonia with diffuse alveolar damage pattern. One of the Houston cases had multiple bilateral segmental pulmonary thromboemboli with infarcts and hemorrhages coupled with, in nonhemorrhagic areas, a distinctive interstitial lymphocytic pneumonitis with intra-alveolar fibrin deposits and no hyaline membranes, possibly representing a transition form to acute fibrinous and organizing pneumonia. Multifocal acute injury of cardiac myocytes was frequently observed. Lymphocytic myocarditis was reported in 1 case. In addition to major pulmonary pathology, the 3 Houston cases had evidence of lymphocytic pericarditis, multifocal acute injury of cardiomyocytes without inflammatory cellular infiltrates, depletion of splenic white pulp, focal hepatocellular degeneration and rare glomerular capillary thrombosis. Each had evidence of chronic cardiac disease: hypertensive left ventricular hypertrophy (420 g heart), dilated cardiomyopathy (1070 g heart), and hypertrophic cardiomyopathy (670 g heart). All 3 subjects were obese (BMIs of 33.8, 51.65, and 35.2 Kg/m(2)). Overall, the autopsy findings support the concept that the pathogenesis of severe COVID-19 disease involves direct viral-induced injury of multiple organs, including heart and lungs, coupled with the consequences of a procoagulant state with coagulopathy."],"journal":"Cardiovasc Pathol","authors":["Buja, Louis Maximilian","Wolf, Dwayne","Zhao, Bihong","Akkanti, Bindu","McDonald, Michelle","Lelenwa, Laura","Reilly, Noah","Ottaviani, Giulia","Elghetany, M Tarek","Trujillo, Daniel Ocazionez","Aisenberg, Gabriel M","Madjid, Mohammad","Kar, Biswajit"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32434133","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.carpath.2020.107233","keywords":["autopsy","covid-19","coagulopathy","diffuse alveolar damage","heart","kidney","liver","sars-cov-2","spleen","viral pneumonia"],"locations":["Houston","Texas","microthombi","thromboemboli","Houston","Houston","Houston","obese","Houston","Texas","United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Mechanism","Diagnosis"],"weight":1,"_version_":1667342288377872384,"score":48.54334}]}